LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Other Current Assets

Current assets not reported separately, such as prepaid expenses.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Other Current Assets · Q1 FY2026 · quarter ended Mar 2026

Other current assets rises 58.2% from a year ago

Other current assets stood at $6.14M at the end of Q1 FY2026, up 58.2% from a year earlier and up 352.8% from the prior quarter.

Context

  • Other current assets amounted to 2.3% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.
  • Other current assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether other current assets keeps rising in the next quarterly balance sheet after a +58.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.14M+352.8% QoQ
Last fiscal yearDec 2025
-$2.43M-2230.7% YoY
Year agoMar 2025
$3.88M+58.2% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+58.2%——
1 year-2230.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
(2.43M) USD
Year-over-year change
-2230.7%

Other Current Assets vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so other current assets is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +58.2% is the 7th highest of 11, against a peer median of +147.1%.
  • Other current assets amounts to 2.3% of total assets for LENZ, versus a peer median of 1.4%.
LENZ Competitors
Other Current Assets for LENZ and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ABUSArbutus Biopharma CorporationMar 2026$180.47M USD+6082.7%-24.5%65.1%
GERNGeron CorporationMar 2026$140.15M USD+1513.3%+203.1%26.2%
TYRATyra Biosciences, Inc.Mar 2026$11.15M USD+191.6%+15.9%2.7%
LENZLENZ Therapeutics, Inc.Mar 2026$6.14M USD+58.2%—2.3%
SPRYARS Pharmaceuticals, Inc.Mar 2026$5.99M USD+521.8%+72.7%2.1%
GHRSGH Research PLCMar 2026$4.91M USD+47.8%—1.8%
PRMEPrime Medicine, Inc.Mar 2026$2.39M USD-85.5%+144.9%0.8%
SVRASavara Inc.Mar 2026$1.62M USD+102.6%—0.7%
RZLTRezolute, Inc.Mar 2026$1.18M USD-35.9%—0.9%
NBTXNanobiotix S.A.Dec 2025€2K EUR+300.0%-90.3%0.0%
MRVIMaravai LifeSciences Holdings, Inc.Jun 2026$0 USD-100.0%-19.7%0.0%
Peer median (excluding LENZ) —+147.1%+15.9%1.4%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents18.31M44.44M35.14M20.16M25.18M
Short-term Investments0220.5M30.65M188.87M267.17M
Net Receivables00002.43M
Inventory00000
Other Current Assets16K2.2M1.45M114K(2.43M)
Total Current Assets18.32M46.64M67.24M211.92M292.35M
Property, Plant & Equipment (Net)10K279K372K1.99M1.92M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets2K31K2.76M1.4M2.54M
Total Non-current Assets12K310K3.13M3.39M4.46M
Total Assets18.34M46.95M70.38M215.3M305.88M
Account Payables460K4.76M5.71M4.26M4.17M
Short-term Debt00000
Tax Payables0347K000
Deferred Revenue00000
Other Current Liabilities00000
Total Current Liabilities1.25M9.5M18.51M10.41M21.19M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities31.3M61.47M144.38M00
Total Non-current Liabilities31.3M61.62M144.57M814K350K
Total Liabilities32.55M71.12M163.09M11.22M21.54M
Common Stock1K10K10K1K1K
Retained Earnings(14.47M)(25.28M)(95.25M)(145.01M)(227.14M)
Accumulated OCI0(1.05M)6K196K242K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(14.21M)(24.17M)(92.71M)204.08M284.34M
Total Debt0250K329K1.38M815K
Net Debt(18.31M)(44.19M)(34.81M)(18.78M)(24.36M)

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.